Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI-1607 in Combination with Ipilimumab and Pembrolizumab in Unresectable or Metastatic Melanoma
2024-512670-10-00Phase 2Completed
- Sponsor
- BioInvent International
- Start
- Jan 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 4
01
Overview
Phase 2, open-label, single-arm trial of BI-1607 in melanoma, sponsored by BioInvent International. Primary endpoints: Occurrence of dose-limiting toxicities (DLTs), Objective response and survival outcomes (RECIST v1.1 and iRECIST) and 5 more. Started Jan 2025; status: completed.
02
Drugs
BI-1607
03
Conditions
melanoma
Beyond the preview
Go deeper on 2024-512670-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512670-10-00.